Posted on :

August 1, 2022

Kolosis BIO Announces the Appointment of Michelle Soleimani-Mafi as Director of Operations

Salt Lake City, Utah, August 1, 2022

Kolosis BIO, a privately-held pure-play orthobiologics company, announced today the appointment of Michelle Soleimani-Mafi as its Director of Operations.

“Success in our industry is built through responsiveness to our customers. There’s no other way. Michelle from day one provides experienced leadership to our operations group delivering on our promise of Relentless Execution,” said Maxwell Hunter, Chief Operating Officer. “She’s built a reputation over years for her passionate commitment to her customers and I look forward to her impact here at Kolosis.”

Prior to joining Kolosis, Michelle spent 16 years at Orthofix where she ultimately held the position of Regional Manager representing MTF bone graft tissues.

“I’m delighted to be a part of what Kolosis is building and to reunite with a team that I’ve known for years,” said Michelle Soleimani-Mafi. “Our combination of best-in-class technologies from MTF with this team’s commercial prowess is truly exciting and I look forward to being a big part of the success story here at Kolosis!”

About Kolosis BIO:

Kolosis BIO is a pure-play orthobiologics company dedicated to commercializing Bold Technologies with Relentless Execution. Kolosis exclusively partners with MTF to deliver market-leading bone graft technologies in the orthopedic space. The company represents two MTF bone graft technologies; Kore Fiber, a 100% cortical fiber allograft, and Prime HD, a pre-hydrated DBM. Both grafts offer superior quality through MTF’s proprietary aseptic processing methods which optimally preserve matrix structures and osteoinductive properties. For more information visit